Temsirolimus Patent Expiration
Temsirolimus is used for treating metastatic papillary renal cell carcinoma. It was first introduced by Pf Prism Cv
Temsirolimus Patents
Given below is the list of patents protecting Temsirolimus, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Torisel |
US8791097 (Pediatric) | Anti-tumor activity of CCI-779 in papillary renal cell cancer | Nov 10, 2032 | Pf Prism Cv |
| Torisel | US8791097 | Anti-tumor activity of CCI-779 in papillary renal cell cancer | May 10, 2032 | Pf Prism Cv |
| Torisel |
US8026276 (Pediatric) | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant | Jul 20, 2026 | Pf Prism Cv |
| Torisel | US8026276 | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant | Jan 20, 2026 | Pf Prism Cv |
| Torisel |
US8299116 (Pediatric) | CCI-779 concentrate formulations |
Jan 25, 2024
(Expired) | Pf Prism Cv |
| Torisel |
US8455539 (Pediatric) | CCI-779 concentrate formulations |
Jan 25, 2024
(Expired) | Pf Prism Cv |
| Torisel |
US8722700 (Pediatric) | CCI-779 formulations for parenteral administration |
Jan 25, 2024
(Expired) | Pf Prism Cv |
| Torisel | US8299116 | CCI-779 concentrate formulations |
Jul 25, 2023
(Expired) | Pf Prism Cv |
| Torisel | US8455539 | CCI-779 concentrate formulations |
Jul 25, 2023
(Expired) | Pf Prism Cv |
| Torisel | US8722700 | CCI-779 formulations for parenteral administration |
Jul 25, 2023
(Expired) | Pf Prism Cv |
| Torisel |
USRE44768 (Pediatric) | Rapamycin hydroxyesters |
Aug 15, 2019
(Expired) | Pf Prism Cv |
| Torisel | USRE44768 | Rapamycin hydroxyesters |
Feb 15, 2019
(Expired) | Pf Prism Cv |
| Torisel |
US5362718 (Pediatric) | Rapamycin hydroxyesters |
Oct 18, 2014
(Expired) | Pf Prism Cv |
| Torisel | US5362718 | Rapamycin hydroxyesters |
Apr 18, 2014
(Expired) | Pf Prism Cv |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Temsirolimus's patents.
Latest Legal Activities on Temsirolimus's Patents
Given below is the list recent legal activities going on the following patents of Temsirolimus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical
| 17 Jun, 2024 | US8299116 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2023 | US8026276 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Dec, 2021 | US8791097 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Oct, 2021 | US8722700 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Sep, 2020 | US8455539 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Mar, 2020 | US8299116 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Feb, 2019 | US8026276 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Dec, 2017 | US8791097 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Oct, 2017 | US8722700 |
| Email Notification Critical
| 14 Nov, 2016 | US8455539 |
Temsirolimus's Family Patents
